KR20040007631A - 티아졸 ｐｐａｒ-리간드 및 이의 다형체의 제조 방법 - Google Patents

티아졸 ｐｐａｒ-리간드 및 이의 다형체의 제조 방법 Download PDF

Info

Publication number
KR20040007631A
KR20040007631A KR10-2003-7015677A KR20037015677A KR20040007631A KR 20040007631 A KR20040007631 A KR 20040007631A KR 20037015677 A KR20037015677 A KR 20037015677A KR 20040007631 A KR20040007631 A KR 20040007631A
Authority
KR
South Korea
Prior art keywords
compound
methyl
acid
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7015677A
Other languages
English (en)
Korean (ko)
Inventor
티에리 보이에르
캐롤린 제인 데이
앤드류 조나단 화이트헤드
리차드 안쏘니 헨슨
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20040007631A publication Critical patent/KR20040007631A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
KR10-2003-7015677A 2001-05-31 2002-05-29 티아졸 ｐｐａｒ-리간드 및 이의 다형체의 제조 방법 Ceased KR20040007631A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0113232.3 2001-05-31
GBGB0113232.3A GB0113232D0 (en) 2001-05-31 2001-05-31 Chemical process
PCT/EP2002/005884 WO2002096893A1 (en) 2001-05-31 2002-05-29 Process for preparing a thialzole ppar-ligand and polymorphs thereof

Publications (1)

Publication Number Publication Date
KR20040007631A true KR20040007631A (ko) 2004-01-24

Family

ID=9915637

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7015677A Ceased KR20040007631A (ko) 2001-05-31 2002-05-29 티아졸 ｐｐａｒ-리간드 및 이의 다형체의 제조 방법

Country Status (22)

Country Link
US (1) US7244849B2 (enExample)
EP (1) EP1395572B1 (enExample)
JP (1) JP2004532265A (enExample)
KR (1) KR20040007631A (enExample)
CN (1) CN1551871A (enExample)
AT (1) ATE315556T1 (enExample)
AU (1) AU2002317764B2 (enExample)
BR (1) BR0209892A (enExample)
CA (1) CA2448101A1 (enExample)
CO (1) CO5540298A2 (enExample)
CZ (1) CZ20033256A3 (enExample)
DE (1) DE60208682T2 (enExample)
ES (1) ES2256493T3 (enExample)
GB (1) GB0113232D0 (enExample)
HU (1) HUP0400117A3 (enExample)
IL (1) IL158641A0 (enExample)
MX (1) MXPA03010943A (enExample)
NO (1) NO20035313L (enExample)
NZ (1) NZ529486A (enExample)
PL (1) PL367114A1 (enExample)
WO (1) WO2002096893A1 (enExample)
ZA (1) ZA200308570B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1517882A1 (en) 2002-06-19 2005-03-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
EP1734930A2 (en) * 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
CN101400663A (zh) * 2006-01-10 2009-04-01 史密丝克莱恩比彻姆公司 {2-甲基-4-[4-甲基-2-(4-三氟甲基苯基)噻唑-5-基甲硫基]苯氧基}-乙酸的多晶型
US20140112992A1 (en) * 2011-06-06 2014-04-24 Hetero Research Foundation Process for febuxostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1395572A1 (en) 2004-03-10
ES2256493T3 (es) 2006-07-16
BR0209892A (pt) 2004-06-08
CZ20033256A3 (en) 2004-04-14
DE60208682D1 (de) 2006-04-06
EP1395572B1 (en) 2006-01-11
JP2004532265A (ja) 2004-10-21
NZ529486A (en) 2005-12-23
DE60208682T2 (de) 2006-08-24
CO5540298A2 (es) 2005-07-29
IL158641A0 (en) 2004-05-12
AU2002317764B2 (en) 2005-01-06
GB0113232D0 (en) 2001-07-25
PL367114A1 (en) 2005-02-21
US7244849B2 (en) 2007-07-17
WO2002096893A1 (en) 2002-12-05
ZA200308570B (en) 2005-02-03
CA2448101A1 (en) 2002-12-05
HUP0400117A2 (hu) 2005-03-29
NO20035313L (no) 2003-12-09
ATE315556T1 (de) 2006-02-15
US20040242657A1 (en) 2004-12-02
CN1551871A (zh) 2004-12-01
HUP0400117A3 (en) 2005-09-28
MXPA03010943A (es) 2004-02-27
NO20035313D0 (no) 2003-11-28

Similar Documents

Publication Publication Date Title
EP1244642B1 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators
ES2295352T3 (es) Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas.
JPS6154792B2 (enExample)
WO2002002542A1 (fr) Compose annulaire a cinq chainons
JP2000515133A (ja) 血糖降下性および脂質低下性の化合物
JP2004517100A (ja) ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
KR20040007631A (ko) 티아졸 ｐｐａｒ-리간드 및 이의 다형체의 제조 방법
KR100859591B1 (ko) Ｈｐｐａｒ-알파 수용체의 옥사졸/티아졸-유도체 활성제
AU2002317764A1 (en) Process for preparing a thialzole PPAR-ligand and polymorphs thereof
US20070167628A1 (en) Thiazole-2-carboxamide derivatives for use as hippar agonists in the treatment of i.a. dyslipidemia
RU2263669C2 (ru) Замещенные 8,8a-дигидро-3ah-индено [1,2-d] тиазолы, способ их получения и их применение в качестве лекарственных средств
ZA200204241B (en) Substituted oxazoles and thiazoles derivatives as HPPAR Alpha Activators.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071105

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080307

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071105

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I